Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins

Mechanisms of Ageing and Development

Volumn 122, Issue 9, 2001, Pages 945-962

  Butterfield, D Allan ^a   Kanski, Jaroslaw ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Age related neurodegenerative disorders; Aggregated proteins; Brain protein oxidation

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; BRAIN PROTEIN; FREE RADICAL;

AGING; ALZHEIMER DISEASE; BRAIN NERVE CELL; CELL LOSS; CREUTZFELDT JAKOB DISEASE; DEGENERATIVE DISEASE; FRONTOTEMPORAL DEMENTIA; HUMAN; HUNTINGTON CHOREA; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOGENESIS; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW;

AGING; ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; ANIMALS; BRAIN; HUMANS; HUNTINGTON DISEASE; NERVE TISSUE PROTEINS; NEURODEGENERATIVE DISEASES; OXIDATION-REDUCTION; PRION DISEASES; SYNUCLEINS;

ANIMALIA;

EID: 0035880007     PISSN: 00476374     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0047-6374(01)00249-4     Document Type: Review

References (114)

1. Aksenov, M.Y., et al., 1996. Glutamine synthetase-induced neurotoxicity accompanied by abrogation of fibril formation and amyloid β-peptide fragmentation. J. Neurochem. 66, 2050-2056.
2. Aksenov, M., et al., 2000. Oxidative modification of creatine kinase BB in Alzheimer's disease brain. J. Neurochem. 74, 2520-2527.
3. Aksenov, M.Y. et al., 2001. Protein oxidation in the Alzheimer's disease brain: analysis of protein carbonyls by immunocytochemistry and two-dimensional western blotting. Neuroscience 103, 373-383.
4. Aksenov, M.Y. et al., 1997. Oxidative modification of glutamine synthetase by amyloid beta peptide. Free Rad. Res. 27, 267-281.
5. Aksenova, M.V., et al., 1999. Oxidation of cytosolic proteins and expression of creatine kinase BB in frontal cortex in different neurodegenerative disorders. Dement. Geriatr. Cogn. Disord. 10, 158-165.
6. Alam, Z.I., et al., 2000. No evidence for increased oxidative damage to lipids, proteins, or DNA in Huntington's disease. J. Neurochem. 75, 840-846.
7. Althaus, J.S., et al., 2000. LC-MS/MS detection of peroxynitrite-derived 3-nitrotyrosine in rat microvessels. Free Rad. Biol. Med. 29, 1085-1095.
8. Beckman, J.S., 1996. Oxidative damage and tyrosine nitration from peroxynitrite. Chem. Res. Toxicol. 9, 836-844.
9. Blanc, E.M., et al., 1997. 4-hydroxynonenal, a lipid peroxidation product, impairs glutamate transport in cortical astrocytes. Glia 22, 149-160.
10. Bodies, A.M., et al., 2000. Toxicity of non-abeta component of Alzheimer's disease amyloid, and N-terminal fragments thereof, correlates to formation of beta-sheet structure and fibrils. Eur. J. Biochem. 267, 2186-2194.
11. Bonilla, E., 2000. Huntington disease. A review. Invest. Clin. 41, 117-141.
12. Brouillet, E., et al., 1999. Replicating Huntington's disease phenotype in experimental animals. Prog. Neurobiol. 59, 427-468.
13. Brown, D.R., Besinger, A., 1998. Prion protein expression and Superoxide dismutase activity. Biochem. J. 334, 423-429.
14. Brown, D.R., et al., 1997a. The cellular prion protein binds copper in vivo. Nature 390, 684-687.
15. Brown, D.R., et al., 1997b. Prion protein-deficient cells show altered response to oxidative stress due to decreased SOD-1 activity. Exp. Neurol. 146, 104-112.
16. Brown, D.R., et al., 2001. Antioxidant activity related to copper binding of native prion protein. J. Neurochem. 76, 69-76.
17. Browne, S.E., et al., 1997. Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann. Neurol. 41, 646-653.
18. Browne, S.E., et al., 1999. Oxidative stress in Huntington's disease. Brain Path. 9, 147-163.
19. Butterfield, D.A., et al., 1997b. Free radical oxidation of brain proteins in accelerated senescence and its modulation by N-tert-butyl-α-phenylnitrone. Proc. Natl. Acad. Sci. USA 94, 674-678.
20. Butterfield, D.A., et al., 1997e. Oxidatively-induced structural alteration of glutamine snthetase assessed by analysis of spin labeled incorporation kinetics: relevance to Alzheimer's disease. J. Neurochem. 68, 2451-2457.
21. Butterfield, D.A., et al., 1999. Amyloid β-peptide-induced oxidative pathways of cell death. Meth. Enzymol. 309, 746-768.
22. Butterfield, D.A. et al., 2001. Brain oxidative stress in animal models of accelerated aging and the age-related neurodegenerative disorders, Alzheimer's disease and Huntington's disease. Curr. Med. Chem, in press.
23. Butterfield, D.A., Stadtman, E.R., 1997. Protein oxidation processes in aging brain. Adv. Cell Aging Gerontol. 2, 161-191.
24. Butterfield, D.A., 1982. Spin labeling in disease. Biol. Magn. Reson. 4, 1-78.
25. Butterfield, D.A., 1997d. Amyloid-associated free radical oxidative stress an neurotoxicity; implications for Alzheimer's disease. Chem. Res. Toxicol. 10, 495-506.
26. Calabrese, V., et al., 2000. NO synthase and NO-dependent signal pathways in brain aging and neurodegenerative disorders: the role oxidant/antioxidant balance. Neurochem. Res. 25, 1315-1341.
27. Chase, T.N., et al., 1979. Huntington's Disease. Raven Press, New York.
28. Christen, Y., 2000. Oxidative stress and Alzheimer disease. Am. J. Clin. Nutr. 71, 621S-629S.
29. Cooper, J., et al., 1998. Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Hum. Mol. Genet. 7, 783-790.
30. Davies, S.W., et al., 1998. Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions? Lancet 351, 131-133.
31. El-Agnaf, O.M.A., Irvine, G.B., 2000. Review: formation and properties of amyloid-like fibrils derived from α-synuclein and related proteins. J. Struct. Biol. 130, 300-309.
32. Esterbauer, H., et al., 1991. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Rad. Biol. Med. 11, 81-128.
33. Gamblin, T.C., et al., 2000. Oxidative regulation of fatty acid-induced tau polymerization. Biochemistry 39, 14203-14210.
34. Gentchev, M., et al., 2000. Evidence for oxidative stress in experimental prion disease. Neurobiol. Dis. 7, 270-273.
35. George, J.M., et al., 1995. Characterization of a novel protein regulated during the critical period for song learning in the zebra finch. Neuron 15, 361-372.
36. Giasson, B.I., et al., 2000. Oxidative damage linked to neurodegeneration by selective a-synuclein nitration in synucleinopathy lesions. Science 290, 985-989.
37. Good, P.P., et al., 1998. Protein nitration in Parkinson's disease. J. Neuropathol. Exp. Neurol. 57, 338-342.
38. Good, T.A., Rymer, D.L., 2000. The role of prion peptide structure and aggregation in toxicity and membrane binding. J. Neurochem. 75, 2536-2545.
39. Hall, N.C., et al., 1995. Ischemia/reperfusion induced changes in membrane proteins and lipids of gerbil cortical synaptosomes. Neuroscience 64, 81-89.
40. Harris, M.E., et al., 1995. β-amyloid peptide-derived, oxygen-dependent free radicals inhibit glutamate uptake in cultured astrocytes: implications to Alzheimer's disease. NeuroReport 6, 1875-1879.
41. +-dependent glutamate uptake in rat hippocampal astrocyte cultures. J. Neurochem. 67, 277-286.
42. Hashimoto, M., et al., 1999. Oxidative stress induces amyloid-like aggregate formation of NACP/α-synuclein in vitro. NeuroReport 10, 717-721.
43. Hensley, K., et al., 1994. Electron paramagnetic resonance investigation of free radical induced alterations in neocortical synaptosomal membrane protein infrastructure. Free Rad. Biol. Med. 17, 321-331.
44. Hensley, K., et al., 1995. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J. Neurochem. 65, 2146-2156.
45. Hensley, K., et al., 1998. Eletrochemical analysis of protein nitrotyrosine and dityrosine in the Alzheimer brain indicated region-specific accumulation. J. Neurosci. 18, 8126-8132.
46. Hsiao, K., et al., 1991. Mutation of the prion protein in Libian Jews with Creutzfeld-Jakob disease. New Engl. J. Med. 324, 1091-1097.
47. Huang, X., et al., 2000. Alzheimer's disease, beta-amyloid protein and zinc. J. Nutr. 130, 1488S-1492S.
48. Iwai, A., 2000. Properties of NACP/α-synuclein and its role in Alzheimer's disease. Biochim. Biophys. Acta 1502, 95-109.
49. Jakes, R., et al., 1994. Identification of two distinct synucleins from human brain. FEES Lett. 345, 27-32.
50. Jolivalt, C., et al., 2000. Differential oxidation of apolipoprotein E isoforms and interaction with phospholipids. Free Rad. Biol. Med. 28, 129-140.
51. Keller, J., et al., 2000. Decreased levels of proteasome activity and proteasome expression in aging spinal cord. Neuroscience 98, 149-156.
52. Keller, J.N., Mattson, M.P., 1998. Roles of lipid peroxidation in modulation of cellular signaling pathways, cell dysfunction, and death in the nervous system. Rev. Neurosci. 9, 105-115.
53. Khatoon, S., et al., 1989. Aberrant guanosine triphosphate-beta-tubulin interaction in Alzheimer's disease. Ann. Neurol. 26, 210-215.
54. Klement, I., et al., 1998. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 95, 41-53.
55. Koppal, T., et al., 1998. Vitamin E protects against amyloid peptide (25-35)-induced changes in neocortical synaptosomal membrane lipid structure and composition. Brain Res. 786, 270-273.
56. Koppal, T., et al., 1999. Peroxynitrite-induced alteractions in synaptosomal membrane proteins: insight into oxidative stress in Alzheimer's disease. J. Neurochem. 72, 310-317.
57. Kruger, R., et al., 1998. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18, 106-108.
58. Kuemmerle, S., et al., 1999. Huntingtin aggregates may not predict neuronal death in Huntington's disease. Ann. Neurol. 46, 842-849.
59. LaFontaine, M.A., et al., 2000a. 3-nitropropionic acid induced in vivo protein oxidation in striatal and cortical synaptosomes: insights into Huntington's disease. Brain Res. 858, 356-362.
60. LaFontaine, M.A., et al., 2000b. Effect of exogenous and endogenous antioxidants on 3-nitropionic acid-induced in vivo oxidative stress and striatal lesions: insights into Huntington's disease. J. Neurochem. 75, 1709-1715.
61. Lauderback, C.M. et al., 2001. Vulnerability of synaptosomes from apoe knock-out mice to structural and oxidative modifications induced by Aβ(l-40): implications for Alzheimer's disease. Biochemistry. 40, 2548-2554.
62. Leventhal, L., et al., 2000. Cyclosporin A protects striatal neurons in vitro and in vivo from 3-nitropropionic acid toxicity. J. Comp. Neurol. 425, 471-478.
63. Levine, R.L., et al., 1996. Methionine residues as endogenous antioxidants in proteins. Proc. Natl. Acad. Sci. USA 93, 15036-15040.
64. Lorenzo, A., Yankner, B.A., 1994. β-amyloid neurotoxicity requires fibril formation and is inhibited by Congo red. Proc. Natl. Acad. Sci. USA 91, 12243-12247.
65. Lovell, M.A., et al., 1998. Cooper, iron and zinc in Alzheimer's disease senile plaques. J. Neurol. Sci. 158, 47-52.
66. 2+ homeostasis and cell death. J. Neurosci. 15, 6239-6249.
67. Mark, R.J., et al., 1997. A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid β-peptide. J. Neurochem. 68, 255-264.
68. Markesbery, W.R., Carney, J.M., 1999. Oxidative alterations in Alzheimer's disease. Brain Path. 9, 133-146.
69. Markesbery, W.R., 1997. Oxidative stress hypothesis in Alzheimer's disease. Free Rad. Biol. Med. 23, 134-147.
70. McKinley, M.P., et al., 1991. Scrapie prion rod formation in vitro requires both detergent extraction and limited proteolysis. J. Virol. 65, 1340-1351.
71. Milhaver, O., et al., 2000. Prion infection impairs the cellular response to oxidative stress. Proc. Natl. Acad. Sci. USA 97, 13937-13942.
72. Montine, T.J., et al., 1999. Cerebrospinal fluid F2-isoprostances are elevated in Huntington's disease. Neurology 52, 1104-1105.
73. Oda, T., et al., 1995. Clusterin (apo J) alters the aggregation of amyloid β peptide (Aβ 1-42) and forms slowly sedimenting Aβ complexes that cause oxidative stress. Exp. Neurol. 136, 22-31.
74. Palmer, M.S., et al., 1991. Homozygous prion protein genotype predisposes to sporadic CreutzfeldJakob disease. Nature 352, 340-342.
75. Pedersen, W.A., et al., 2000. A mechanism for the neuroprotective effect of apolipoprotein E: isoform-specific modification by the lipid peroxidation product 4-hydroxynonenal. J. Neuroche m. 74, 1426-1433.
76. Perez-Severiano, F., et al., 2000. Striatal oxidative damage parallels the expression of a neurological phenotype in mice transgenic for the mutation of Huntington's disease. Brain Res. 862, 234-237.
77. Pillot, T., et al., 2000. A nonfibral form of the fusogenic prion protein fragment [118-135] induces apoptotic cell death in rat cortical neurons. J. Neurochem. 75, 2298-2308.
78. Pocernich, C.B. et al., 2001. Glutathione elevation and its protective role in acrolein-induced protein damage in synaptosomal membranes: Relevance to brain lipid peroxidation in neurodegenerative disease. Neurochem. Int, in press.
79. Polidori, M.C., et al., 1999. Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex. Neurosci. Lett. 272, 53-56.
80. Polymeropoulos, M.H., et al., 1997. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science 276, 2045-2047.
81. Prasad, M.R., et al., 1998. Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem. Res. 23, 81-88.
82. Prusiner, S.B., et al., 1990. Transgenic studies implicate interactions between homologous PrP isoforms in scrapie prion replication. Cell 63, 673-686.
83. Prusiner, S.B., 1998. Prions. Proc. Natl. Acad. Sci. USA 95, 13363-13383.
84. Ramassamy, C., et al., 1999. Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. Free Rad. Biol. Med. 27, 544-553.
85. Riederer, P., et al., 1989. Transition metals, ferritin, glutathione, and ascorbic acid in Parkinsonian brains. J. Neurochem. 52, 515-520.
86. Ross, C.A., 1997. Intranuclear neuronal: a common pathogenic mechanism for glutamine-repeat neurodegenerative disease? Neuron 19, 1147-1150.
87. Saha, A.R., et al., 2000. Induction of neuronal death by alpha-synuclein. Eur. J. Neurosci. 12, 3073-3077.
88. Saudou, F., et al., 1998. Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95, 55-66.
89. Schmechel, D.E., et al., 1993. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA 90, 9649-9653.
90. Selkoe, D.J., 1994. Alzheimer's disease: a central role of amyloid. J. Neuropathol. Exp. Neurol. 53, 438-447.
91. Smith, C.D., et al., 1991. Excess brain protein oxidation and enzyme disfunction in normal aging and Alzheimer's disease. Proc. Natl. Acad. Sci. USA 88, 10540-10543.
92. Smith, M.A., et al., 1996. Cytochemical demonstration of oxidative damage in Alzheimer disease by immunochemical enhancement of the carbonyl reaction with 2,4-dinitrophenylhydrazine. J. Histochem. Cytochem. 46, 731-735.
93. Smith, M.A., et al., 1997. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci. 17, 2653-2657.
94. Smith, M.A., et al., 2000. Oxidative stress in Alzheimer's disease. Biochim. Biophys. Acta 1502, 139-144.
95. Souza, J.M., et al., 2000. Dityrosine cross-linking promotes formation of stable oc-synuclein polymers. J. Biol. Chem. 275, 18344-18349.
96. Spillantini, M.G., et al., 1997. Synuclein in lewy bodies. Nature 388, 839-840.
97. Stadtman, E.R., Berlett, B.S., 1998. Reactive oxygen-mediated protein oxidation in aging and disease. Drug Metab. Rev. 30, 225-243.
98. Subramaniam, R., et al., 1998. The free radical antioxidant vitamin E protects cortical synaptosomal membrane proteins from amyloid β-peptide (25-35) toxicity but not from hydroxynonenal toxicity: relevance to the free radical hypothesis of Alzheimer's disease. Neurochem. Res. 23, 1403-1410.
99. Subramaniam, R., et al., 1997. The lipid peroxidation product, 4-hydroxy-2-trans-nonenal, alters the conformation of cortial synaptosomal membrane proteins. J. Neurochem. 69, 1161-1169.
100. Swaab, D.E., et al., 1998. Reduced neuronal activity and reactivation in Alzheimer's disease. Prog. Brain Res. 117, 343-377.
101. Tabrizi, S.J., Schapira, A.H., 1999. Secondary abnormalities of mitochondrial DNA associated with neurodegeneration. Biochem. Soc. Symp. 66, 99-110.
102. Varadarajan, S., et al., 1999. Methionine residue 35 is important in amyloid β-peptide-associated free radical oxidative stress. Brain Res. Bull. 50, 133-141.
103. Varadarajan, S., et al., 2000a. Review: Alzheimer's amyloid β-peptide-associated free radical oxidative stress and neurotoxicity. J. Struct. Biol. 130, 184-208.
104. Varadarajan, S., et al., 2000b. Alzheimer's amyloid β-peptide (1-42) fibrils are not always toxic. Alzheimer's Rep. 3, 71-76.
105. Viles, J.H., et al., 1999. Copper binding to the prion protein: structural implications of four identical cooperative binding sites. Proc. Natl. Acad. Sci. USA 96, 2042-2047.
106. Vitek, M.P., et al., 1997. Modulation of nitric oxide production in human macrophages by apolipoprotein-E and amyloid-beta peptide. Biochem. Biophys. Res. Commun. 240, 391-394.
107. Walsh, D.M., et al., 1999. Amyloid beta-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J. Biol. Chem. 274, 25945-25952.
108. Wong, B.-S., et al., 1999. Selective oxidation of methionine residues in prion proteins. Biochem. Biophys. Res. Commun. 259, 352-355.
109. Wong, B.-S., et al., 2000a. Prion disease: a loss of antioxidant function? Biochem. Biophys. Res. Commun. 275, 249-252.
110. Wong, B.-S., et al., 2000b. Differential contribution of Superoxide dismutase activity by prion protein in vivo. Biochem. Biophys. Res. Commun. 273, 136-139.
111. Wong, B.-S., et al., 2001. Increased levels of oxidative stress markers detected in the brains of mice devoid of prion protein. J. Neurochem. 76, 565-572.
112. Yatin, S.M., et al., 1999a. The antioxidant vitamin E modulates amyloid β-peptide-induced creatine kinase activity inhibition and increased protein oxidation: implications for the free radical hypothesis of Alzheimer's disease. Neurochem. Res. 24, 427-435.
113. Yatin, S.M., et al., 1999b. In-vitro and in-vivo oxidative stress associated with Alzheimer's amyloid β-peptide (1-42). Neurobiol. Aging 20, 325-330.
114. Yatin, S.M., et al., 2000. Vitamin E prevents Alzheimer's amyloid β-peptide (l-42)-induced protein oxidation and reactive oxygen species formation. J. Alzheimer's Dis. 2, 123-131.